63. 特発性血小板減少性紫斑病 Idiopathic thrombocytopenic purpura Clinical trials / Disease details

臨床試験数 : 391 / 薬物数 : 235 - (DrugBank : 50) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 139

22 trials found

diseases per page:

Showing 1 to 10 of 22 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2200057058	2022-07-01	2022-02-27	A Single-Arm Prospective Exploratory Clinical Study Of Zanubrutinib Combined With RituximabIn The Tr ...	A Single-Arm Prospective Exploratory Clinical Study Of Zanubrutinib Combined With RituximabIn The Tr ...	Primary Immune Thrombocytopenia	Therapy Group:Zanubrutinib(80 mg, 2 times/day, for a total of 12 weeks) combined with Rituximab(375 ...	The Second Affiliated Hospital of Kunming Medical University	NULL	Pending	18	70	Both	Therapy Group:23;	Phase 1	China
2	NCT05338190 (ClinicalTrials.gov)	June 1, 2022	21/3/2022	Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximabin Persistent or Ch ...	A Phase 3 Randomized and Double-blind Controlled Trial Comparing the Efficacy and Safety of Subcutan ...	Primary Immune Thrombocytopenia (ITP)	Drug: Combination of Rituximab with subcutaneous belimumab;Drug: Combination of Rituximabwith subcuta ...	Assistance Publique - Hôpitaux de Paris	GlaxoSmithKline	Not yet recruiting	18 Years	N/A	All	132	Phase 3	NULL
3	ChiCTR2000035408	2020-08-20	2020-08-10	A randomized controlled study for rituximabin first-line treatment of newly diagnosed immune thrombo ...	Study of rituximab in first-line treatment of newly diagnosed immune thrombocytopenia	Idiopathic Thrombocytopenic Purpura	Standard dose group:Rituximab(Hanrikang) 375mg/m2, 4 times a week (day 8, 15, 22, 29).;Low-dose grou ...	Henan Cancer Hospital	NULL	Recruiting	18	65	Both	Standard dose group:20;Low-dose group:20;Dexamethasone control group:20;	Phase 4	China
4	NCT04518475 (ClinicalTrials.gov)	August 10, 2020	12/8/2020	Eltrombopag Combining RituximabVersus Eltrombopag in the Management of Primary Immune Thrombocytopen ...	A Multicenter, Randomized, Open-label Study To Compare The Efficacy And Safety Of Eltrombopag Combin ...	Primary Immune Thrombocytopenia (ITP)	Drug: eltrombopag combining rituximab;Drug: eltrombopag	Institute of Hematology & Blood Diseases Hospital	The Second Affiliated Hospital of Kunming Medical University;Henan Cancer Hospital;Tianjin Medical U ...	Recruiting	18 Years	60 Years	All	224	Phase 4	China
5	ChiCTR1900027748	2020-05-01	2019-11-25	A single-arm multicenter prospective clinical study of rituximab500 mg/m2 in glucocorticoid-ineffect ...	A single-arm multicenter prospective clinical study of rituximab500 mg/m2 in glucocorticoid-ineffect ...	Primary Immune Thrombocytopenia	Test group:Rituximab (500mg/m2, once intravenously);	Department of Hematology, the Second Affiliated Hospital of Kunming Medical University	NULL	Recruiting			Both	Test group:60;	Phase 4	China
6	ChiCTR2000030603	2020-05-01	2020-03-08	A multicenter prospective cohort clinical study of a short-course glucocorticoid therapy regimen for ...	A multicenter prospective cohort clinical study of a short-course glucocorticoid therapy regimen for ...	Primary Immune Thrombocytopenia	The short -course glucocorticoid group:treat with glucocorticoid;The eltrombopaggroup:treat with elt ...	The Second Affiliated Hospital of Kunming Medical University	NULL	Recruiting	18	75	Both	The short -course glucocorticoid group:65;The eltrombopag group:65;The rituximab group:65;Splenectomy group:65;The azathioprine group:65;The cyclosporine group:65;	Phase 4	China
7	NCT03443570 (ClinicalTrials.gov)	March 1, 2018	18/2/2018	Rituximab Combining Bortezomib Versus Rituximab in Management of ITP	A Multicenter Prospective Randomized Study of RituximabCombined With Bortezomib Versus Rituximabin t ...	Immune Thrombocytopenia;Purpura, Thrombocytopenic, Idiopathic	Drug: Rituximab;Drug: Bortezomib	Shandong University	The Affiliated Hospital of Qingdao University;Yantai Yuhuangding Hospital	Not yet recruiting	18 Years	75 Years	All	200	Phase 3	China
8	EUCTR2015-005276-14-DK (EUCTR)	08/12/2016	19/10/2016	Maintenance treatment With rituximab in ITP	Prolonging the response by low-dose Rituximabmaintenance therapy in immune thrombocytopenia: a rando ...	Immune thrombocytopenia MedDRA version: 23.0;Level: LLT;Classification code 10021245;Term: Idiopathi ...	Trade Name: Mabthera Product Name: rituximab Trade Name: Dexamethasone Abcur Product Name: Dexamethasone ...	Sykehuset Østfold HF	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	France;Egypt;Denmark;Norway;Tunisia
9	NCT01734057 (ClinicalTrials.gov)	July 2012	21/11/2012	Recombinant Human Thrombopoietin (rhTPO) Combining RituximabVersus High-dose Dexamethasone for Initi ...	A Multicentre Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining RituximabVersus Hi ...	Purpura;Idiopathic Thrombocytopenic Purpura	Drug: recombinant human thrombopoietin (rhTPO); rituximab;Drug: Dexamethasone	Shandong University	The Affiliated Hospital of the Chinese Academy of Military Medical Sciences;Anhui Medical University ...	Withdrawn	18 Years	75 Years	Both	0	Phase 3	China
10	JPRN-JMA-IIA00070	31/10/2011	12/08/2011	R-ITP: Clinical Evaluation of Rituximab in Primary Immune Thrombocytopenia	R-ITP: Clinical Evaluation of Rituximab in Primary Immune Thrombocytopenia	Idiopathic Thrombocytopenic Purpura	Intervention type:DRUG. Intervention1:rituximab, Dose form:INJECTION, Route of administration:INTRAV ...	Keio University School of Medicine , Yoshitaka miyakawa	NULL	Completed	>=20 YEARS	No Limit	BOTH	24	Phase 3	Japan

First Previous1 2 3Next Last